RNDr. Tomáš GUCKÝ, Ph.D.

Avatar
Contact

585631471,725526066

Katedra experimentální biologie

Přírodovědecká fakulta

Šlechtitelů 27-objekt 48 (VTP, blok A)

1.09

odborný asistent

ČLÁNEK
Břehová P., Řezníčková E., Škach K., Jorda R., Vojáčková V., Kovalová M., Kinnertová M., Gucký T., Kryštof V. Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2-b]pyridazine Derivatives Identified by Scaffold Hopping. JOURNAL OF MEDICINAL CHEMISTRY. 2023.
Vlková K., Padrtová R., Gucký T., Peřina M., Řezníčková E., Kryštof V. Synthesis and biological activity evaluation of novel 3,5,7-trisubstituted pyrazolo[1,5-a]pyrimidines. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2023.
Vlková K., Gucký T., Peřina M., Řezníčková E., Kryštof V. Synthesis and biological activity evaluation of novel 2,6,9-trisubstituted purine conjugates as potential protein kinases inhibitors. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. 2022.
Hrdlička J., Gucký T., van Staden J., Novák O., Doležal K. A stable isotope dilution method for a highly accurate analysis of karrikins. Plant Methods. 2021.
Jansa J., Jorda R., Škerlová J., Peřina M., Řezníčková E., Heger T., Gucký T., Kryštof V. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2021.
Špičáková A., Kraus P., Gucký T., Kryštof V., Strnad M., Bazgier V., Otyepka M., Kubíčková V., Poruba M., Rácová Z., Zapletalová I., Anzenbacher P. In vitro and in silico studies of interaction of synthetic 2,6,9-trisubstituted purine kinase inhibitors BPA-302, BP-21 and BP-117 with liver drug-metabolizing cytochromes P450. PHYSIOLOGICAL RESEARCH. 2020.
Gupta S., Hrdlička J., Ngoroyemoto N., Gucký T., Novák O., Doležal K. Preparation and Standardisation of Smoke-Water for Seed Germination and Plant Growth Stimulation. JOURNAL OF PLANT GROWTH REGULATION. 2020.
Řezníčková E., Gucký T., Kováčová V., Ajani H., Jorda R., Kryštof V. Activity of 2,6,9-trisubstituted purines as potent PDGFR alpha kinase inhibitors with antileukaemic activity. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. 2019.
Béres T., Černochová L., Ćavar Zeljković S., Benická S., Gucký T., Berčák M., Tarkowski P. Intralaboratory comparison of analytical methods for quantification of major phytocannabinoids. ANALYTICAL AND BIOANALYTICAL CHEMISTRY. 2019.
Hrdlička J., Gucký T., Novák O., Kulkarni M., Gupta S., van Staden J., Doležal K. Quantification of karrikins in smoke water using ultra-high performance liquid chromatography-tandem mass spectrometry. Plant Methods. 2019.
Voller J., Zahajská L., Plíhalová L., Jeřábková J., Burget D., Pataki AC., Kryštof V., Zatloukal M., Brábek J., Rosel D., Mik V., Tkáč M., Pospíšil T., Gucký T., Doležal K., Strnad M. 6-Substituted purines as ROCK inhibitors with anti-metastatic activity. BIOORGANIC CHEMISTRY. 2019.
Gucký T., Řezníčková E., Radošová Muchová T., Jorda R., Klejová Z., Malínková V., Berka K., Bazgier V., Ajani HB., Lepšík M., Divoký V., Kryštof V. Discovery of N-2-(4-Amino-cyclohexyl)-9-cyclopentyl-N-6-(4-morpholin-4-ylmethyl-phenyl)-9H-purine-2,6-diamine as a Potent FLT3 Kinase Inhibitor for Acute Myeloid Leukemia with FLT3 Mutations. JOURNAL OF MEDICINAL CHEMISTRY. 2018.
Jorda R., Hendrychová D., Voller J., Řezníčková E., Gucký T., Kryštof V. How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases? JOURNAL OF MEDICINAL CHEMISTRY. 2018.
Široká J., Čečková M., Urbánek L., Kryštof V., Gucký T., Hofman J., Strnad M., Štaud F. LC-MS/MS method for determination of cyclin-dependent kinase inhibitors, BP-14 and BP-20, and its application in pharmacokinetic study in rat. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES. 2018.
Krajčovičová S., Gucký T., Hendrychová D., Kryštof V., Soural M. A Stepwise Approach for the Synthesis of Folic Acid Conjugates with Protein Kinases Inhibitors. Journal of Organic Chemistry. 2017.
Zahajská L., Nisler J., Voller J., Gucký T., Pospíšil T., Spíchal L., Strnad M. Preparation, characterization and biological activity of C8-substituted cytokinins. Phytochemistry. 2017.
Malínková V., Řezníčková E., Jorda R., Gucký T., Kryštof V. Trisubstituted purine inhibitors of PDGFR alpha and their antileukemic activity in the human eosinophilic cell line EOL-1. Bioorganic & Medicinal Chemistry. 2017.
Řezníčková E., Weitensteiner S., Havlíček L., Jorda R., Gucký T., Berka K., Bazgier V., Zahler S., Kryštof V., Strnad M. Characterization of a Pyrazolo[4,3-d]pyrimidine Inhibitor of Cyclin-dependent Kinases 2 and 5 and Aurora A With Pro-Apoptotic and Anti-Angiogenic Activity In Vitro. Chemical Biology and Drug Design. 2015.
Řezníčková E., Popa A., Gucký T., Zatloukal M., Havlíček L., Bazgier V., Berka K., Jorda R., Popa I., Nasereddin A., Jaffe CL., Kryštof V., Strnad M. 2,6,9-Trisubstituted purines as CRK3 kinase inhibitors with antileishmanial activity in vitro. Bioorganic & Medicinal Chemistry Letters. 2015.
Mojzych M., Šubertová V., Bielawska A., Bielawski K., Bazgier V., Berka K., Gucký T., Fornal E., Kryštof V. Synthesis and kinase inhibitory activity of new sulfonamide derivatives of pyrazolo[4,3-e][1,2,4]triazines. European Journal of Medicinal Chemistry. 2014.
Gucký T., Jorda R., Zatloukal M., Bazgier V., Berka K., Řezníčková E., Béres T., Strnad M., Kryštof V. A Novel Series of Highly Potent 2,6,9-Trisubstituted Purine Cyclin-Dependent Kinase Inhibitors. Journal of Medicinal Chemistry. 2013.
Haider C., Grubinger M., Řezníčková E., Weiss T., Rotheneder H., Miklos W., Berger W., Jorda R., Zatloukal M., Gucký T., Strnad M., Kryštof V., Mikulits W. Novel Inhibitors of Cyclin-Dependent Kinases Combat Hepatocellular Carcinoma without Inducing Chemoresistance. Molecular Cancer Therapeutics. 2013.
Zatloukal M., Jorda R., Gucký T., Řezníčková E., Voller J., Pospíšil T., Malínková V., Adamcová H., Kryštof V., Strnad M. Synthesis and in vitro biological evaluation of 2,6,9-trisubstituted purines targeting multiple cyclin-dependent kinases. European Journal of Medicinal Chemistry. 2013.
Weitensteiner SB., Liebl J., Kryštof V., Havlíček L., Gucký T., Strnad M., Fuerst R., Vollmar AM., Zahler S. Trisubstituted Pyrazolopyrimidines as Novel Angiogenesis Inhibitors. PLoS One. 2013.
Fülöpová V., Gucký T., Grepl M., Soural M. Solid-Phase Synthesis of Trisubstituted Benzo[1,4]-Diazepin-5-one Derivatives. ACS Combinatorial Science. 2012.
Kvapil L., ŠIMÁČEK A., Grepl M., GUCKÝ T., POSPÍŠIL T., HRADIL P. Simple and Efficient Synthesis of N-Nitroethylenediamine Derivatives. Synlett. 2011.
Gucký T., Řezníčková E., Džubák P., Hajdúch M., Kryštof V. Synthesis and anticancer activity of some 1,5-diaryl-3-(3,4,5-trihydroxyphenyl)-1H-pyrazolo[4,3-e][1,2,4]triazines. Monatshefte für Chemie. 2010.
Walla J., Szüčová L., Císařová I., Gucký T., Zatloukal M., Doležal K., Greplová J., Massino FJ., Strnad M. X-ray structure, NMR and stability-in-solution study of 6-(furfurylamino)-9-(tetrahydropyran-2-yl)purine - A new active compound for cosmetology. Journal of Molecular Structure. 2010.
Fryšová I., Růžičková V., Slouka J., Gucký T. The use of α-ketoacids for syntheses of heterocyclic compounds I. Synthesis and oxidative cyclization of some substituted benzimidazol-2-yl-formazanes. Acta Universitatis Palackianae Olomucensis, Facultas Rerum Naturalium, Chemica. 2005.
PŘÍSPĚVEK VE SBORNÍKU
Fryšová I., Slouka J., Gucký T. A SIMPLE SYNTHESIS OF SOME BENZIMIDAZOLE-2-CARBOXAMIDE ARYLHYDRAZONES AND STUDY OF THEIR STRUCTURE. 20th International Congress of Heterocyclic Chemistry. 2005.
KNIHA - CELEK
Stýskala J., Gucký T., Fryšová I. Cvičení z organické chemie. Cvičení z organické chemie. 2005.
PATENT, UŽITNÝ VZOR, PRŮMYSLOVÝ VZOR
Gucký T., Řezníčková E., Jorda R., Kryštof V., Strnad M., Radošová Muchová T., Divoký V. 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions. 2021.
Gucký T., Řezníčková E., Jorda R., Kryštof V., Strnad M., Radošová Muchová T., Divoký V. 2,6-disubstituted-9-cyclopentyl-9H-purines, use thereof as medicaments, and pharmaceutical compositions. 2021.
Gucký T., Řezníčková E., Jorda R., Divoký V., Kryštof V., Radošová Muchová T., Strnad M. 2,6-disubstituované-9-cyklopentyl-9H-puriny, jejich použití jako léčiva a farmaceutické přípravky. 2019.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2017.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Strnad M., Mikulits W. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2016.
Strnad M., Mikulits W., Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2016.
Gucký T., Jorda R., Zatloukal M., Kryštof V., Rárová L., Řezníčková E., Mikulits W., Strnad M. 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, use thereof as medicaments, and pharmaceutical compositions. 2016.
ABSTRAKT
Kořalková P., Niederlová N., Hradilová I., Gurský J., Chaloupková P., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V. Targeting of SFK and CAMK Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations. Hematologie 2023. 2023.
Niederlová N., Kořalková P., Chaloupková P., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V. Targeting of tyrosine kinases contributing to KMT2A-r mediated leukemogenesis as a therapeutic approach in mixed-lineage leukemia. Czech Annual Cancer Research Meeting (abstract book). 2023.
Niederlová N., Kořalková P., Chaloupková P., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcová D., Beličková M., Kryštof V., Divoký V. Unique kinase inhibitor targeting specifically MLL/FLT3-mediated signaling for personalized medicine in AML. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2023.
Kořalková P., Niederlová N., Hradilová I., Gurský J., Čudová B., Urbánková H., Řezníčková E., Gucký T., Myslivcova D., Belickova M., Kryštof V., Divoký V. Targeting of SFK and G6PD Contributes to Anti-Leukemic Activity of Novel FLT3 Trisubstituted Purine Inhibitors: Effective Therapeutic Approach for AML with FLT3 Mutations. Blood. 2022.
Radošová Muchová T., Řezníčková E., Somíková Z., Gucký T., Strnad M., Kryštof V., Divoký V. A Novel Dual Class III/Src Family Tyrosine Kinase Inhibitor Is Highly Active Against FLT3-ITD Leukemia Cells In Vivo. Blood (online). 2016.
PROTOTYP, FUNKČNÍ VZOREK
Gucký T., Řezníčková E., Malínková V., Kryštof V. Soubor purinových inhibitorů FLT3-ITD kinázy. 2018.

Uživatel nepovolil zobrazení dat v Portále UP.

Doctoral study on UP

Name Faculty Study programme Year of completion
VLKOVÁ PRF Biologie 2023
List contains doctoral study graduates

Privacy settings

We use cookies and any other network identifiers on our website that may contain personal data (e.g. about how you browse our website). We and some of the service providers we use have access to or store this data on your device. This data helps us to operate and improve our services. For some purposes, your consent is required to process data collected in this way. You can change or revoke your consent at any time (see the link at the bottom the page).

(Essential cookies enable basic functions and are necessary for the website to function properly.)
(Statistics cookies collect information anonymously. This information helps us to understand how our visitors use our website.)
(They are designed for promotional purposes, measuring the success of promotional campaigns, etc.)